» Articles » PMID: 1261759

Inhibition of Gastric Acid Secretion in Man by Exogenous and Endogenous Pancreatic Glucagon

Overview
Specialty Gastroenterology
Date 1976 May 1
PMID 1261759
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of intravenously infused glucagon and pentagastrin on gastric acid secretion was studied in 5 healthy subjects. First a step dose-response study with pentagastrin in doses of 0.01, 0.1,1.0, and 10.0 mug per kg-hr was performed. The dose required for one-half maximal response (D50) was 130 ng per kg-hr. With this dose of pentagastrin as background stimulation a step dose-response study with glucagon in doses of 0.5, 2.0, 8.0, and 16.0 mug per kg-hr was performed. The dose of glucagon required for one-half maximal inhibition was 1.64 mug per kg-hr. In a third experiment the dose-response study with pentagastrin was repeated on a background infusion of glucagon in the dose found to be D50. A significant inhibition of acid secretion was found on all dose levels. The inhibition followed noncompetitive kinetics. Plasma concentrations of pancreatic glucagon in 4 of the 5 subjects in this experiment were comparable concentrations seen after a protein meal. Intravenous infusion of l-arginine on a background stimulation of acid secretion with synthetic human gastrin I in a dose of 250 ng per kg-hr was performed in 7 healthy subjects. Arginine increased serum glucagon concentration to levels seen after a meal and resulted in a significant inhibition of acid secretion. The results favor the hypothesis that pancreatic glucagon may participate in the physiological inhibition of gastric acid secretion.

Citing Articles

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

Wettergren A, Schjoldager B, Mortensen P, MYHRE J, Christiansen J, Holst J Dig Dis Sci. 1993; 38(4):665-73.

PMID: 8462365 DOI: 10.1007/BF01316798.


Effect of endogenous pancreatic glucagon on gastric acid secretion in patients with duodenal ulcer before and after parietal cell vagotomy.

Loud F, Chirstiansen J, Holst J, Petersen B, Kirkegaard P Gut. 1981; 22(5):359-62.

PMID: 7250747 PMC: 1419251. DOI: 10.1136/gut.22.5.359.


Pancreatic glucagon in human foetal stomach.

Buchan A, Bryant M, Stein B, Gregor M, Ghatei M, Morris J Histochemistry. 1982; 74(4):515-20.

PMID: 7107326 DOI: 10.1007/BF00496665.


Effect of pentagastrin on parietal cell ultrastructure in glucagon-pretreated subjects.

Ivey K, Tarnawski A, Krause W, Stachura J, Sherman D, Burks M Dig Dis Sci. 1982; 27(5):394-400.

PMID: 7075426 DOI: 10.1007/BF01295646.


Interaction of glucagon and pentagastrin on pepsin secretion in healthy subjects.

Christiansen J, Holst J, Molin J Gut. 1982; 23(6):528-31.

PMID: 6804315 PMC: 1419707. DOI: 10.1136/gut.23.6.528.